Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP12 - Tumor Biology and Systems Biology - Basic and Translational Science
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
FP12.09 - Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.
00:00 - 00:00 | Presenter: Raquel Laza Briviesca
- Abstract
Loading...
-
+
FP13 - Immunotherapy (Phase II/III Trials)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
-
+
FP13.01 - 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC
00:00 - 00:00 | Presenter: Roy S. Herbst
- Abstract
Loading...
-
+
P48 - Small Cell Lung Cancer/NET - Chemo - IO
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/NET
-
+
P48.04 - IMfirst; Phase IIIB Safety Study of Atezolizumab Plus Chemotherapy in a Real World Population of Untreated ES-SCLC
00:00 - 00:00 | Presenter: Rosario Garcia Campelo
- Abstract
Loading...
-
+
P60 - Tumor Biology and Systems Biology - Basic and Translational Science - Immune Bio
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
P60.07 - TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial
00:00 - 00:00 | Presenter: Alberto Cruz-Bermudez
- Abstract
Loading... -
+
P60.11 - TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial
00:00 - 00:00 | Presenter: Marta Casarrubios
- Abstract
Loading...
-
+
OA06 - Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Early Stage/Localized Disease
-
+
OA06.03 - Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
16:45 - 16:55 | Presenter: Margarita Majem
- Abstract
Loading... -
+
OA06.04 - Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
16:55 - 17:05 | Presenter: Yi-long Wu
- Abstract
Loading...
-
+
MA08 - Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma
- 16:45 - 17:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
MA08.04 - LIPI and Outcomes of Durvalumab as Consolidation Therapy after ChRT in Patients with Locally-Advanced NSCLC
16:50 - 16:55 | Presenter: Mariona Riudavets
- Abstract
Loading...
